Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $30.8 million.

  • X4 Pharmaceuticals' Non-Current Assets fell 1262.47% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.6 million, marking a year-over-year increase of 925.52%. This contributed to the annual value of $34.3 million for FY2024, which is 3609.72% up from last year.
  • Per X4 Pharmaceuticals' latest filing, its Non-Current Assets stood at $30.8 million for Q3 2025, which was down 1262.47% from $32.2 million recorded in Q2 2025.
  • X4 Pharmaceuticals' Non-Current Assets' 5-year high stood at $41.1 million during Q1 2021, with a 5-year trough of $24.8 million in Q1 2024.
  • For the 5-year period, X4 Pharmaceuticals' Non-Current Assets averaged around $31.1 million, with its median value being $29.3 million (2021).
  • Per our database at Business Quant, X4 Pharmaceuticals' Non-Current Assets tumbled by 3046.19% in 2022 and then soared by 3844.07% in 2024.
  • Over the past 5 years, X4 Pharmaceuticals' Non-Current Assets (Quarter) stood at $29.3 million in 2021, then decreased by 8.15% to $26.9 million in 2022, then fell by 6.42% to $25.2 million in 2023, then surged by 36.1% to $34.3 million in 2024, then fell by 10.28% to $30.8 million in 2025.
  • Its last three reported values are $30.8 million in Q3 2025, $32.2 million for Q2 2025, and $34.3 million during Q1 2025.